Dominari (NASDAQ:DOMH) Releases Earnings Results

Dominari (NASDAQ:DOMH) issued its quarterly earnings results on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, Zacks reports. Dominari had a negative net margin of 36.01% and a negative return on equity of 94.32%.

Dominari Trading Up 0.4%

Shares of DOMH stock opened at $4.78 on Monday. The stock has a fifty day simple moving average of $6.12 and a two-hundred day simple moving average of $5.62. The stock has a market capitalization of $76.47 million, a price-to-earnings ratio of -2.02 and a beta of 0.66. Dominari has a twelve month low of $0.83 and a twelve month high of $13.58.

Dominari Dividend Announcement

The company also recently announced a special dividend, which was paid on Friday, September 26th. Shareholders of record on Wednesday, September 3rd were given a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, September 3rd.

Institutional Trading of Dominari

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Dominari by 8.0% during the third quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock valued at $2,452,000 after purchasing an additional 25,694 shares in the last quarter. Jane Street Group LLC acquired a new position in Dominari during the 2nd quarter valued at about $158,000. Finally, Geode Capital Management LLC boosted its holdings in Dominari by 2.9% in the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock worth $361,000 after acquiring an additional 1,866 shares in the last quarter. Hedge funds and other institutional investors own 42.48% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on DOMH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dominari in a research note on Wednesday, October 8th. Wall Street Zen raised Dominari from a “sell” rating to a “buy” rating in a research report on Saturday, August 16th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.